[SCHEDULE 13G/A] PTC Therapeutics, Inc. SEC Filing
Armistice Capital and Steven Boyd report collective ownership of 4,735,464 shares of PTC Therapeutics common stock, representing 5.96% of the class. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises shared voting and dispositive power. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Armistice Capital e Steven Boyd dichiarano di detenere congiuntamente 4.735.464 azioni ordinarie di PTC Therapeutics, pari al 5,96% della relativa categoria. Le azioni sono possedute da Armistice Capital Master Fund Ltd., per la quale Armistice Capital svolge il ruolo di gestore degli investimenti e esercita poteri condivisi di voto e disposizione. Steven Boyd, in qualit脿 di membro direttivo di Armistice Capital, 猫 indicato con gli stessi poteri condivisi di voto e disposizione. La comunicazione precisa che i titoli sono stati acquisiti e sono detenuti nell'ambito normale dell'attivit脿 commerciale e non con l'intento di modificare o influenzare il controllo dell'emittente.
Armistice Capital y Steven Boyd informan de la propiedad conjunta de 4.735.464 acciones ordinarias de PTC Therapeutics, lo que representa el 5,96% de la clase. Las acciones est谩n en manos de Armistice Capital Master Fund Ltd., para la cual Armistice Capital act煤a como gestor de inversiones y ejerce poderes compartidos de voto y disposici贸n. Steven Boyd, como miembro directivo de Armistice Capital, figura con los mismos poderes compartidos de voto y disposici贸n. La presentaci贸n indica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Armistice Capital瓿� Steven Boyd電� PTC Therapeutics 氤错喌欤� 4,735,464欤茧ゼ 瓿惦彊 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 欤检嫕 韥措灅鞀れ潣 5.96%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 頃措嫻 欤检嫕鞚� Armistice Capital鞚� 韴瀽 甏�毽瀽 鞐暊鞚� 頃橁碃 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 頄夓偓頃橂姅 Armistice Capital Master Fund Ltd.臧� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Armistice Capital鞚� 甏�毽� 氅る矂鞚� Steven Boyd霃� 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 鞛愲 氤搓碃霅╇媹雼�. 鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 旆摑 氚� 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital et Steven Boyd d茅clarent d茅tenir conjointement 4 735 464 actions ordinaires de PTC Therapeutics, repr茅sentant 5,96 % de la cat茅gorie. Les actions sont d茅tenues par Armistice Capital Master Fund Ltd., pour laquelle Armistice Capital agit en tant que gestionnaire d'investissement et exerce des pouvoirs partag茅s de vote et de disposition. Steven Boyd, en tant que membre dirigeant d'Armistice Capital, est signal茅 avec les m锚mes pouvoirs partag茅s de vote et de disposition. Le d茅p么t pr茅cise que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Armistice Capital und Steven Boyd melden gemeinschaftlichen Besitz von 4.735.464 Stammaktien von PTC Therapeutics, was 5,96% der Klasse entspricht. Die Aktien werden von der Armistice Capital Master Fund Ltd. gehalten, f眉r die Armistice Capital als Investmentmanager fungiert und gemeinsame Stimm- und Verf眉gungsrechte aus眉bt. Steven Boyd wird als gesch盲ftsf眉hrendes Mitglied von Armistice Capital mit denselben gemeinsamen Stimm- und Verf眉gungsrechten angegeben. Die Meldung stellt klar, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
- Armistice Capital reports beneficial ownership of 4,735,464 shares of PTC Therapeutics common stock
- Position represents 5.96% of the outstanding class, a material disclosure level under SEC thresholds
- Filing states shares are held in the ordinary course and not to influence control, clarifying passive intent
- None.
Insights
TL;DR: A 5.96% passive stake disclosed by an investment manager signals notable ownership but no intent to seek control.
Armistice Capital discloses beneficial ownership of 4,735,464 shares (5.96%), held via its Master Fund with Armistice exercising shared voting and dispositive power. This Schedule 13G/A presentation classifies the position as held in the ordinary course and not intended to influence control, which is consistent with passive investor behavior. For investors, a near-6% stake by an active investment manager is material for share-register concentration and potential future engagement, but the filing contains no operative actions or strategic changes.
TL;DR: Disclosure clarifies voting and disposition arrangements and confirms the filer is not pursuing control.
The filing attributes shared voting and dispositive power to Armistice Capital and Steven Boyd while the Master Fund is the direct holder. The Master Fund disclaims beneficial ownership by virtue of its agreement with the manager, and the filing includes a certification that the position is not intended to change control. From a governance standpoint, this clarifies roles and responsibilities but does not indicate activism or control-seeking conduct.
Armistice Capital e Steven Boyd dichiarano di detenere congiuntamente 4.735.464 azioni ordinarie di PTC Therapeutics, pari al 5,96% della relativa categoria. Le azioni sono possedute da Armistice Capital Master Fund Ltd., per la quale Armistice Capital svolge il ruolo di gestore degli investimenti e esercita poteri condivisi di voto e disposizione. Steven Boyd, in qualit脿 di membro direttivo di Armistice Capital, 猫 indicato con gli stessi poteri condivisi di voto e disposizione. La comunicazione precisa che i titoli sono stati acquisiti e sono detenuti nell'ambito normale dell'attivit脿 commerciale e non con l'intento di modificare o influenzare il controllo dell'emittente.
Armistice Capital y Steven Boyd informan de la propiedad conjunta de 4.735.464 acciones ordinarias de PTC Therapeutics, lo que representa el 5,96% de la clase. Las acciones est谩n en manos de Armistice Capital Master Fund Ltd., para la cual Armistice Capital act煤a como gestor de inversiones y ejerce poderes compartidos de voto y disposici贸n. Steven Boyd, como miembro directivo de Armistice Capital, figura con los mismos poderes compartidos de voto y disposici贸n. La presentaci贸n indica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Armistice Capital瓿� Steven Boyd電� PTC Therapeutics 氤错喌欤� 4,735,464欤茧ゼ 瓿惦彊 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 欤检嫕 韥措灅鞀れ潣 5.96%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 頃措嫻 欤检嫕鞚� Armistice Capital鞚� 韴瀽 甏�毽瀽 鞐暊鞚� 頃橁碃 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 頄夓偓頃橂姅 Armistice Capital Master Fund Ltd.臧� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Armistice Capital鞚� 甏�毽� 氅る矂鞚� Steven Boyd霃� 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 鞛愲 氤搓碃霅╇媹雼�. 鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 旆摑 氚� 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital et Steven Boyd d茅clarent d茅tenir conjointement 4 735 464 actions ordinaires de PTC Therapeutics, repr茅sentant 5,96 % de la cat茅gorie. Les actions sont d茅tenues par Armistice Capital Master Fund Ltd., pour laquelle Armistice Capital agit en tant que gestionnaire d'investissement et exerce des pouvoirs partag茅s de vote et de disposition. Steven Boyd, en tant que membre dirigeant d'Armistice Capital, est signal茅 avec les m锚mes pouvoirs partag茅s de vote et de disposition. Le d茅p么t pr茅cise que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Armistice Capital und Steven Boyd melden gemeinschaftlichen Besitz von 4.735.464 Stammaktien von PTC Therapeutics, was 5,96% der Klasse entspricht. Die Aktien werden von der Armistice Capital Master Fund Ltd. gehalten, f眉r die Armistice Capital als Investmentmanager fungiert und gemeinsame Stimm- und Verf眉gungsrechte aus眉bt. Steven Boyd wird als gesch盲ftsf眉hrendes Mitglied von Armistice Capital mit denselben gemeinsamen Stimm- und Verf眉gungsrechten angegeben. Die Meldung stellt klar, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle des Emittenten dienen.
FAQ
How many PTC Therapeutics (PTCT) shares does Armistice Capital report owning?
What percentage of PTCT does the reported stake represent?
Who holds voting and dispositive power over the reported securities?
Are the shares held to influence control of PTC Therapeutics?
Which entity is the direct holder of the shares reported?
